Top Stock Reports For AbbVie, Union Pacific & Bristol-Myers
Zacks Investment Research | Nov 01, 2017 04:28AM ET
Wednesday, November 1, 2017
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and Bristol-Myers (BMY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
AbbVie's shares have gained +44.1% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has gained +14.6% over the same period. AbbVie reported mixed Q3 results. While earnings beat estimates, revenues came in line. Humira and Imbruvica kept up the strong performance.
Meanwhile, AbbVie raised its earnings outlook for the year backed by a strong year-to-date performance. Despite new competition, it raised its long-term target for Humira sales based on strong demand trends for the drug.
The Zacks analyst stresses that the past 2-3 months have been strong for the company as it presented promising data from several pivotal studies, gained regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settled its Humira patent disputes with Amgen (NASDAQ:AMGN).
Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition.
(You can ) .
Shares of Buy-rated Union Pacific have outperformed the Zacks Rail Transportation Industry as well as fellow railroad operator Kansas City Southern (NYSE:KSU) over the last three months. While the company has gained +13.1%, the industry in belongs to and Kansas City Southern have rallied +8.3% and +2.1%, respectively, so far this year.
Ushering in further good news, Union Pacific reported better-than-expected earnings per share and revenues in the third quarter of 2017. Results were aided by strong performances of the company's intermodal and industrial products units.
The Zacks analyst is impressed by the company's efforts to cut costs to drive its bottom line as well. Efforts to reward investors also raise optimism in the stock. However, declining coal revenues in the third quarter raise concerns. Automotive volumes also decreased due to sluggish vehicle production in the United States.
Get The News You Want
(You can ) .
Strong Buy-rated Bristol-Myers shares have underperformed the broader market as well as the Zacks Large Cap Pharmaceuticals industry this year, gaining only +5.5% in the year-to-date period. Bristol-Myers reported mixed results for the third-quarter with earnings missed expectations although revenue beat on the same. The miss in earnings was attributable to lower gross margin which in turn was due to product mix and decline in virology business.
The Zacks analyst thinks the increase in earnings guidance is encouraging. The company’s blockbuster immuno-oncology Opdivo continues to perform well along with Eliquis and Orencia. The company is looking to expand Opdivo’s label further and recently won FDA approvals for liver and colorectal cancers which should boost performance.
The company is also looking to counter generic threat for its key drugs through deals and acquisitions. The company recently entered into a deal with AbbVie and Halozyme. However, Opdivo is currently facing competitive challenges in the United States. The virology business is also under pressure.
(You can ) .
Other noteworthy reports we are featuring today include Xilinx (NASDAQ:XLNX) (XLNX), Weyerhaeuser (WY) and Colgate (CL).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly
Today's Must Read/h6
Featured Reports/h6
The Zacks analyst appreciates the company's efforts to check costs. Strong box-office revenues also raise optimism in the stock.
Per the Zacks analyst, Weyerhaeuser can use the proceeds from the sale of its 21% interest in Twin Creeks to develop its core timber, land and forest products business.
Per the Zacks analyst, Principal Financial's increasing expenses weigh on margin expansion.
he Zacks analyst points out that in Q3, AbbVie presented promising data from several pivotal studies, gained approval for HCV medicine Mavyret and settled its Humira patent disputes with Amgen.
Per the Zacks analyst, increased demand for FlexPath programs should drive Capella's top line growth.
Per the Zacks analyst, IPG Photonics is benefiting from the strong adoption of fiber lasers over conventional lasers and non-laser cutting and welding equipment.
Per the Zacks analyst, improving premiums continue to boost CNA Financial's revenues, thereby boosting the company's overall growth.
The Zacks analyst appreciates the company's efforts to check costs. Strong box-office revenues also raise optimism in the stock.
Per the Zacks analyst, Weyerhaeuser can use the proceeds from the sale of its 21% interest in Twin Creeks to develop its core timber, land and forest products business.
Per the Zacks analyst, Principal Financial's increasing expenses weigh on margin expansion.
he Zacks analyst points out that in Q3, AbbVie presented promising data from several pivotal studies, gained approval for HCV medicine Mavyret and settled its Humira patent disputes with Amgen.
Per the Zacks analyst, increased demand for FlexPath programs should drive Capella's top line growth.
Per the Zacks analyst, IPG Photonics is benefiting from the strong adoption of fiber lasers over conventional lasers and non-laser cutting and welding equipment.
Per the Zacks analyst, improving premiums continue to boost CNA Financial's revenues, thereby boosting the company's overall growth.
New Upgrades/h6
The Zacks analyst believes that Xilinx is focused on tapping emerging technologies like AI, 5G connectivity, autonomous vehicles and IoTs to drive growth over the long run.
The Zacks analyst expects Statoil to generate significant cash flow from new upstream projects in the Norwegian Continental Shelf.
The Zacks analyst believes that world-class discoveries made in the offshore Guyana resources will boost Hess??? crude production.
The Zacks analyst believes that Xilinx is focused on tapping emerging technologies like AI, 5G connectivity, autonomous vehicles and IoTs to drive growth over the long run.
The Zacks analyst expects Statoil to generate significant cash flow from new upstream projects in the Norwegian Continental Shelf.
The Zacks analyst believes that world-class discoveries made in the offshore Guyana resources will boost Hess??? crude production.
New Downgrades/h6
Per the Zacks analyst, Colgate's margins in third-quarter were hurt by increased raw material and packaging costs, and higher advertising expenses, which are likely to persist and hit margins in 2017.
The Zacks analyst is worried about rising costs from Aesynt and Ateb integration and XT series launch costs. Also, tough competion in the medication & supply chain solutions market is a worry.
Vornado's portfolio pruning efforts are a strategic fit for the long term. However, the earnings dilutive impact cannot be bypassed in the near term.
Per the Zacks analyst, Colgate's margins in third-quarter were hurt by increased raw material and packaging costs, and higher advertising expenses, which are likely to persist and hit margins in 2017.
The Zacks analyst is worried about rising costs from Aesynt and Ateb integration and XT series launch costs. Also, tough competion in the medication & supply chain solutions market is a worry.
Vornado's portfolio pruning efforts are a strategic fit for the long term. However, the earnings dilutive impact cannot be bypassed in the near term.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.